[go: up one dir, main page]

MX2013014788A - Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. - Google Patents

Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.

Info

Publication number
MX2013014788A
MX2013014788A MX2013014788A MX2013014788A MX2013014788A MX 2013014788 A MX2013014788 A MX 2013014788A MX 2013014788 A MX2013014788 A MX 2013014788A MX 2013014788 A MX2013014788 A MX 2013014788A MX 2013014788 A MX2013014788 A MX 2013014788A
Authority
MX
Mexico
Prior art keywords
methyl
organic acids
ino
imidazol
pyridinyl
Prior art date
Application number
MX2013014788A
Other languages
English (en)
Inventor
Shoufeng Li
Saran Kumar
Enxian Lu
Nikhil Javant Kavimandan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013014788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013014788A publication Critical patent/MX2013014788A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se inventaron composiciones farmacéuticas solubles de nilotinib, o de una sal farmacéuticamente aceptable del mismo, utilizando uno o más ácidos orgánicos que funcionan como un agente solubilizante, que aumentan la biodisponibilidad del nilotinib, y que suprimen el efecto del alimento asociado con ciertas composiciones de nilotinib. Las composiciones farmacéuticas están en la forma de formas de dosificación oral sólidas, incluyendo cápsulas y tabletas.
MX2013014788A 2011-06-14 2012-06-13 Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. MX2013014788A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496913P 2011-06-14 2011-06-14
US201161541306P 2011-09-30 2011-09-30
PCT/US2012/042205 WO2012174082A1 (en) 2011-06-14 2012-06-13 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Publications (1)

Publication Number Publication Date
MX2013014788A true MX2013014788A (es) 2014-07-28

Family

ID=46317545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014788A MX2013014788A (es) 2011-06-14 2012-06-13 Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.

Country Status (21)

Country Link
US (1) US20150273070A1 (es)
EP (1) EP2721024A1 (es)
JP (1) JP2014517040A (es)
KR (1) KR20140036225A (es)
CN (1) CN103608342A (es)
AP (1) AP2013007233A0 (es)
AR (1) AR086913A1 (es)
BR (1) BR112013032122A2 (es)
CA (1) CA2838741A1 (es)
CL (1) CL2013003576A1 (es)
CO (1) CO6801777A2 (es)
CR (1) CR20130649A (es)
EA (1) EA201490014A1 (es)
GT (1) GT201300309A (es)
IL (1) IL229395A0 (es)
MX (1) MX2013014788A (es)
PE (1) PE20141318A1 (es)
PH (1) PH12013502277A1 (es)
SG (1) SG194756A1 (es)
TW (1) TW201311246A (es)
WO (1) WO2012174082A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
WO2015130083A1 (ko) * 2014-02-25 2015-09-03 동아에스티 주식회사 용법이 개선된 엔테카비어를 함유하는 약학적 조성물
KR101633292B1 (ko) * 2014-02-25 2016-06-24 동아에스티 주식회사 용법이 개선된 엔테카비어를 함유하는 약학적 조성물
CA2964198C (en) 2014-10-16 2023-03-14 Apotex Inc. Solid forms of nilotinib hydrochloride
CN114209702A (zh) * 2016-03-17 2022-03-22 太阳制药工业公司 尼洛替尼的药物组合物
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN110913842A (zh) * 2017-07-19 2020-03-24 伊尼塔公司 包括恩曲替尼的药物组合物
RS62872B1 (sr) 2017-09-27 2022-02-28 Incyte Corp Soli derivata pirrolotriazina korisne kao tam inhibitori
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
WO2020101597A2 (en) * 2018-08-27 2020-05-22 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule compositions comprising tyrosine-kinase inhibitors
EP4509123A3 (en) * 2019-02-18 2025-05-07 Slayback Pharma LLC Pharmaceutical compositions of nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
CN115968292A (zh) * 2020-07-24 2023-04-14 隆萨本德公司 含乙酸的api过饱和溶液的喷雾干燥
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
AU2021353684A1 (en) 2020-09-29 2023-06-08 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Pharmaceuticals Gmbh Granulate composition comprising nilotinib
EP4122452A1 (en) * 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
US20250144096A1 (en) * 2023-11-08 2025-05-08 Xspray Pharma Ab Pharmaceutical compositions comprising nilotinib

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468845C (en) * 2001-12-03 2011-08-23 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
ES2356257T3 (es) * 2005-06-09 2011-04-06 Novartis Ag Proceso para la síntesis del 5-(metil-1h-imidazol-1-il)-3-(trifluorometil)-bencenoamina.
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CN101228150B (zh) * 2005-07-20 2014-10-15 诺华股份有限公司 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CN101228151B (zh) * 2005-07-20 2013-01-09 诺瓦提斯公司 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的盐
MX2009002031A (es) * 2006-08-25 2009-03-06 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
AU2007316558A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) * 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
US8937082B2 (en) * 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof

Also Published As

Publication number Publication date
SG194756A1 (en) 2013-12-30
KR20140036225A (ko) 2014-03-25
PE20141318A1 (es) 2014-10-13
AP2013007233A0 (en) 2013-11-30
GT201300309A (es) 2015-02-19
US20150273070A1 (en) 2015-10-01
TW201311246A (zh) 2013-03-16
CO6801777A2 (es) 2013-11-29
CR20130649A (es) 2014-02-04
EA201490014A1 (ru) 2014-04-30
CL2013003576A1 (es) 2014-07-11
WO2012174082A1 (en) 2012-12-20
JP2014517040A (ja) 2014-07-17
EP2721024A1 (en) 2014-04-23
BR112013032122A2 (pt) 2016-12-13
PH12013502277A1 (en) 2020-10-19
IL229395A0 (en) 2014-01-30
CA2838741A1 (en) 2012-12-20
AR086913A1 (es) 2014-01-29
CN103608342A (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
PH12015500823A1 (en) Modified release formulations for oprozomib
PH12014501408A1 (en) Immediate release multi unit pellet system
PH12015501945B1 (en) Formulations of organic compounds
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
TR201803451T4 (tr) Olmesartan formülasyonlari.
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
IN2012CH05549A (es)
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
MA35169B1 (fr) Libération modifiée de 4-méthyl-3-[ [4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4- méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl] benzamide solubilisé à l'aide d'acides organiques
TH148311B (th) การปลดปล่อยที่ถูกดัดแปรของ 4-เมธิล-3-[[4-(3-ไพริดินิล)-2-ไพริมิดินิล]อะมิโน]-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟูลออโรเมธิล)ฟีนิล] เบนซาไมด์ที่สามารถละลายได้โดยใช้กรดอินทรีย์
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
ES2422657A1 (es) Composición farmacéutica sólida de cilostazol
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну
IN2013MU01330A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal